Last reviewed · How we verify
METHIMAZOLE
At a glance
| Generic name | METHIMAZOLE |
|---|---|
| Drug class | Thyroid Hormone Synthesis Inhibitor [EPC] |
| Modality | Small molecule |
| Phase | FDA-approved |
| First approval | 1950 |
Approved indications
Common side effects
- Skin rash
- Urticaria
- Nausea
- Vomiting
- Epigastric distress
- Arthralgia
- Paresthesia
- Loss of taste
- Abnormal loss of hair
- Myalgia
- Headache
- Pruritus
Serious adverse events
- Agranulocytosis
- Aplastic anemia
- Hepatitis
- Acute pancreatitis
- Vasculitis with ANCA
- Periarteritis
- Lupus-like syndrome
- Insulin autoimmune syndrome
- Thrombocytopenia
- Granulocytopenia
Drug interactions
- oral anticoagulants (e.g., warfarin)
- beta-adrenergic blocking agents
- digitalis glycosides
- theophylline
Key clinical trials
- Methimazole in Patients With Progressive Glioblastoma (PHASE2)
- Impact of Vitamin D Therapy on Thyroid Function and Antibody Levels in Pediatric Graves' Disease (PHASE2)
- Prospective Evaluation of OptiThyDose (NA)
- A Clinical Follow-up Study on Drug Therapy for Graves' Disease Patients in China
- Hyperthyroidism: Methimazole Plus L-carnitine and Selenium (NA)
- Phase 2 Study to Assess Efficacy & Safety of WP1302 Prevent Relapse of MMI w/Draw in Subj. w/ Graves' dz (PHASE2)
- Efficacy of Methimazole Dosing Algorithm
- A Clinical Study of Hyperthyroidism in Children
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |